Name: CytomX Therapeutics, Inc. (CTMX) Financial Statements
Creator: FinSpry

CytomX Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

CytomX Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	138.10	101.21	53.16	37.31	100.36	57.49	59.50
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	138.10	101.21	53.16	37.31	100.36	57.49	0.00
Operating Expenses
Research & Development	83.38	77.68	106.55	114.19	112.94	131.62	103.87
Selling, General & Administrative	29.73	30.02	40.45	39.16	36.03	36.77	33.51
Operating Expenses	113.11	107.70	147.00	153.35	148.97	168.38	137.38
Operating Income	25.00	-6.48	-93.84	-116.04	-48.61	-110.90	-77.87
Other Income/Expense
Interest Income	7.14	9.84	1.68	0.26	1.84	0.00	7.64
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	7.10	0.03	0.34	-0.08	0.03	0.14	-0.07
Income
Income Before Tax	32.09	3.32	-99.32	-115.87	-46.80	-102.67	-70.30
Income Tax Expense	0.22	3.89	0.00	0.00	-13.91	-0.43	14.30
Net Income	31.87	-0.57	-99.32	-115.87	-64.82	-102.24	-84.60
Net Income - Continuous Operations	31.87	-0.57	-99.32	-115.87	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	26.76	-4.31	-91.39	-113.34	-77.97	-102.29	-75.99
EBIT	25.00	-6.48	-93.84	-116.04	-80.54	-102.67	-77.87
Depreciation & Amortization	1.77	2.18	2.44	2.71	2.40	2.50	0.00
Earnings Per Share
Basic EPS	-	-	-2.00	-2.00	-1.00	-2.00	-2.00
Diluted EPS	-	-	-2.00	-2.00	-1.00	-2.00	-2.00
Basic Shares Outstanding	84.44	73.81	65.74	64.15	46.15	45.34	41.66
Diluted Shares Outstanding	84.75	73.81	65.74	64.15	46.15	45.34	41.66